Evidence map›Paper›PMID 27382104›Full record

Trial reportJournal of clinical oncology : official journal of the American Society of Clinical Oncology2016

Continued Risk of Relapse Independent of Treatment Modality in Limited-Stage Diffuse Large B-Cell Lymphoma: Final and Long-Term Analysis of Southwest Oncology Group Study S8736.

Deborah M Stephens, Hongli Li, Michael L LeBlanc, Soham D Puvvada, Daniel Persky, Jonathan W Friedberg, Sonali M Smith

Abstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
58citing papers in PubMed, 2 pooled it
7.9field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

58 citing papers in PubMed, 2 syntheses or guidelines pooled it, 131 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Trial
  4. Phase 2 Study of Dose-Reduced Consolidation Radiation Therapy in Diffuse Large B-Cell Lymphoma.International journal of radiation oncology, biology, physics · 2019
    Trial
  5. Trial
  6. Trial
  7. Trial
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 7 institutions in 4 countries.

Deborah M StephensDeborah M. Stephens, University of Utah, Salt Lake City, UT; Hongli Li and Michael L. LeBlanc, Southwest Oncology Group Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, WA; Soham D. Puvvada and Daniel Persky, University of Arizona, Tucson, AZ; Jonathan W. Friedberg, Wilmot Cancer Institute, University of Rochester, Rochester, NY; and Sonali M. Smith, University of Chicago, Chicago, IL.
Hongli LiDeborah M. Stephens, University of Utah, Salt Lake City, UT; Hongli Li and Michael L. LeBlanc, Southwest Oncology Group Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, WA; Soham D. Puvvada and Daniel Persky, University of Arizona, Tucson, AZ; Jonathan W. Friedberg, Wilmot Cancer Institute, University of Rochester, Rochester, NY; and Sonali M. Smith, University of Chicago, Chicago, IL.
Michael L LeBlancDeborah M. Stephens, University of Utah, Salt Lake City, UT; Hongli Li and Michael L. LeBlanc, Southwest Oncology Group Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, WA; Soham D. Puvvada and Daniel Persky, University of Arizona, Tucson, AZ; Jonathan W. Friedberg, Wilmot Cancer Institute, University of Rochester, Rochester, NY; and Sonali M. Smith, University of Chicago, Chicago, IL.
Soham D PuvvadaDeborah M. Stephens, University of Utah, Salt Lake City, UT; Hongli Li and Michael L. LeBlanc, Southwest Oncology Group Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, WA; Soham D. Puvvada and Daniel Persky, University of Arizona, Tucson, AZ; Jonathan W. Friedberg, Wilmot Cancer Institute, University of Rochester, Rochester, NY; and Sonali M. Smith, University of Chicago, Chicago, IL.
Daniel PerskyDeborah M. Stephens, University of Utah, Salt Lake City, UT; Hongli Li and Michael L. LeBlanc, Southwest Oncology Group Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, WA; Soham D. Puvvada and Daniel Persky, University of Arizona, Tucson, AZ; Jonathan W. Friedberg, Wilmot Cancer Institute, University of Rochester, Rochester, NY; and Sonali M. Smith, University of Chicago, Chicago, IL.
Jonathan W FriedbergDeborah M. Stephens, University of Utah, Salt Lake City, UT; Hongli Li and Michael L. LeBlanc, Southwest Oncology Group Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, WA; Soham D. Puvvada and Daniel Persky, University of Arizona, Tucson, AZ; Jonathan W. Friedberg, Wilmot Cancer Institute, University of Rochester, Rochester, NY; and Sonali M. Smith, University of Chicago, Chicago, IL.
Sonali M SmithDeborah M. Stephens, University of Utah, Salt Lake City, UT; Hongli Li and Michael L. LeBlanc, Southwest Oncology Group Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, WA; Soham D. Puvvada and Daniel Persky, University of Arizona, Tucson, AZ; Jonathan W. Friedberg, Wilmot Cancer Institute, University of Rochester, Rochester, NY; and Sonali M. Smith, University of Chicago, Chicago, IL. smsmith@medicine.bsd.uchicago.edu.
Bayer (United States) · USBristol-Myers Squibb (Switzerland) · CHSpectrum Pharmaceuticals (United States) · USTakeda (Japan) · JPUniversity of Chicago · USUniversity of Rochester · USUniversity of Utah · US

Funding

SWOG Network Group Operations Center of the NCTNU10CA180888 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI PRIMO N. LARA · 2014 to 2026
$152.1M
SWOG Statistics & Data Management Center complex - extension supplement for GY06U10CA180819 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Catherine M. Tangen · 2014 to 2026
$115.2M
Heartland Cancer Research NCORPUG1CA189830 · NCI · DECATUR MEMORIAL HOSPITAL · PI Bryan A. Faller · 2014 to 2026
$40.9M
Cancer Research Consortium of West Michigan (CRCWM)UG1CA189860 · NCI · COREWELL HEALTH · PI KATHLEEN YOST BUTLER · 2014 to 2026
$29.1M
The Pacific Cancer Research Consortium (PCRC), an NCORP Community SiteUG1CA189953 · NCI · SWEDISH MEDICAL CENTER, FIRST HILL · PI Alison Katherine Conlin, Charles Drescher · 2014 to 2026
$27.4M
Ozark Health Ventures, LLC dba Cancer Research for the Ozarks (CRO)UG1CA189822 · NCI · OZARK HEALTH VENTURES, LLC · PI Jay W Carlson · 2014 to 2026
$14.2M
Dayton Clinical Oncology ProgramUG1CA189957 · NCI · DAYTON CLINICAL ONCOLOGY PROGRAM · PI Howard M Gross · 2014 to 2026
$10.7M
Columbus NCORP RFA-CA-18-016UG1CA189954 · NCI · COLUMBUS COMMUNITY CLINICAL ONCOLOGY PRG · PI Aruna Gowda, Malolan S Rajagopalan · 2014 to 2026
$9.8M
National Community Oncology Research ProjectUG1CA189808 · NCI · VIA CHRISTI REGIONAL MEDICAL CENTER · PI DAKHIL, SHAKER R · 2014 to 2018
$8.6M
Huntsman Cancer Institute/ University of Utah Network Lead Academic Participating Site ApplicationUG1CA233178 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Matthew Poppe, Heloisa Prado Soares · 2019 to 2026
$4.9M
Northwest NCI Community Oncology Research ProgramUG1CA189952 · NCI · TACOMA GENERAL HOSPITAL · PI AMOROSO, PAUL J., KEECH, JOHN A · 2014 to 2018
$4.5M
University of Colorado NTCN Lead Academic Participating Site (LAPS) U10CA180834 · NCI · UNIVERSITY OF COLORADO DENVER · PI ELIAS, ANTHONY D · 2014 to 2018
$3.8M
NCI NIH HHS U10 CA180801NCI NIH HHS U10 CA180818NCI NIH HHS U10 CA180819NCI NIH HHS U10 CA180828NCI NIH HHS U10 CA180830NCI NIH HHS U10 CA180834NCI NIH HHS U10 CA180835NCI NIH HHS U10 CA180846NCI NIH HHS U10 CA180888NCI NIH HHS UG1 CA180830NCI NIH HHS UG1 CA189808NCI NIH HHS UG1 CA189822NCI NIH HHS UG1 CA189830NCI NIH HHS UG1 CA189853NCI NIH HHS UG1 CA189860NCI NIH HHS UG1 CA189952NCI NIH HHS UG1 CA189953NCI NIH HHS UG1 CA189954NCI NIH HHS UG1 CA189957NCI NIH HHS UG1 CA233178
6 · The paper itself

Abstract

purposeUtility of combined-modality therapy for patients with limited-stage diffuse large B-cell lymphoma (DLBCL) was shown in the Southwest Oncology Group (SWOG) S8736 study, where three cycles of CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) plus radiotherapy (CHOP3RT) improved 5-year progression-free (PFS) and overall survival (OS) compared with eight cycles of CHOP (CHOP8). Subsequent analysis showed an unexpected overlap of the PFS curves. We aimed to confirm and investigate this observation by performing long-term analysis of SWOG S8736 and evaluating these data alongside data from similar patients receiving rituximab and CHOP3RT (SWOG S0014 study). PATIENTS AND

methodsA subset of patients with limited-stage DLBCL randomly assigned to CHOP8 (n = 150) or CHOP3RT (n = 158) in S8736 was analyzed along with a 56-patient subset treated in S0014 for long-term PFS and OS.

resultsMedian follow-up in S8736 was 17.7 years. In patients receiving CHOP8 and CHOP3RT, median PFS was 12.0 (95% CI, 8.8 to 14.3) and 11.1 years (95% CI, 8.9 to 14.4), respectively. There were no statistically significant differences in PFS between the groups (P = .73). Median OS was 13.0 (95% CI, 10.4 to 15.2) and 13.7 years (95% CI, 11.1 to 19.4) for patients treated with CHOP8 and CHOP3RT, respectively. Similarly, there were no statistically significant differences in OS between the groups (P = .38). With a median follow-up time 12 years in S0014, 5- and 10-year OS were 82% and 67%, respectively, with a persistent pattern of relapse despite the addition of rituximab.

conclusionAlthough 5-year PFS and OS were improved after early analysis in patients with limited-stage DLBCL receiving CHOP3RT versus CHOP8, extended survival data showed similar PFS and OS, with continuous treatment failure. The addition of rituximab (S0014) to combined-modality therapy did not mitigate the continued relapse risk, underscoring the value of prolonged clinical trial patient observation and possible unique biology of limited-stage DLBCL.

Indexed as

AdolescentAdultAgedAged, 80 and overAntibodies, Monoclonal, Murine-DerivedAntineoplastic Combined Chemotherapy ProtocolsChemoradiotherapyCyclophosphamideDisease-Free SurvivalDoxorubicinHumansLymphoma, Large B-Cell, DiffuseMiddle AgedNeoplasm StagingPrednisolonePrednisoneAntibodies, Monoclonal, Murine-DerivedCyclophosphamideDoxorubicinPrednisolonePrednisoneR-CHOP protocolRituximabVincristine

Identifiers

PMID27382104
PMCPMC5012710
OpenAlexW2475270667

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.